Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Pfizer's Osivelotor?
Osivelotor is a small molecule commercialized by Pfizer, with a leading Phase III program in Sickle Cell Disease. According to...
Osivelotor by Pfizer for Sickle Cell Disease: Likelihood of Approval
Osivelotor is under clinical development by Pfizer and currently in Phase III for Sickle Cell Disease. According to GlobalData, Phase...
Osivelotor by Pfizer for Liver Failure (Hepatic Insufficiency): Likelihood of Approval
Osivelotor is under clinical development by Pfizer and currently in Phase I for Liver Failure (Hepatic Insufficiency). According to GlobalData,...